Claims
- 1. Pyrrolo�3,2-e!indole derivatives, characterized in that they have the following formulae (I) (Ia) and (II): ##STR30## wherein R represents an aryl or heteroaryl group, substituted or not substituted, R' represents alkanoyl, alkenoyl, alkynoyl, arenocarbonyl or heteroarenocarbonyl, substituted or not substituted and X represents chlorine, bromine, iodine or alkyl or arylsulfonyl.
- 2. A pyrrolo�3,2-e! derivatives, according to claim 1, characterized in that R represents an indolyl group or an indolyl group substituted with an aryl or an heteroarylcarbonylamino group.
- 3. A pyrrolo�3,2-e!indol derivative, according to claim 1, characterized in that it has the following formulae (III): ##STR31##
- 4. A pyrrolo�3,2-e!indol derivative, according to claim 1, characterized in that it has the following formula (IV): ##STR32##
- 5. A pyrrolo�3,2-e!indol derivative, according to claim 1, characterized in that it has the following formula (V): ##STR33##
- 6. A pyrrolo�3,2-e!indol derivative, according to claim 1, characterized in that it has the following formula (VI): ##STR34##
- 7. A pyrrolo�3,2-e!indol derivative, according to claim 1, characterized in that it has the following formula (IIIa): ##STR35##
- 8. A pyrrolo�3,2-e!indol derivative, according to claim 1, chracterized in that it has the following formula (IIIb): ##STR36##
- 9. A process for the preparation of pyrrolo�3,2-e!indol derivatives, of general formulae (I), (Ia) and (II): ##STR37## wherein R represents aryl or heteroaryl, substituted or not substited, R' represents alkanoyl, alkenoyl, alkynoyl arenocarbonyl or heteroarenocarbonyl, substituted or not substituted and X represents chlorine, bromine, iodine or alkyl-or arylsulfonyl; whose process is characterized in that it comprises the following steps:
- a) subjecting to deacylation reaction a compound of formula (VII): ##STR38## wherein Ac represents an acyl group, by treating the same with a base in an organic solvent, to produce the compound of formula (VIII): ##STR39## b) subjecting the compind (VIII) thus obtained to a reaction to open the cyclopropyl ring, by means of treating the same with an acid in an organic solvent, to produce the compound of formula (IX): ##STR40## wherin X has the meaning given above for formula (I); c) subjecting the compound (IX) thus obtained to a condensation reaction with an acid of formula
- R--COOH (X)
- wherein R has the meaning given above, or a reactive derivative of the same, to produce the active compound of formula (I) indicated above, carrying out said condensation in an organic solvent and in the presence of a condensing agent:
- d) when necessary, treating the compounds of formula (I) thus obtained with a base in a suitable solvent to produce the compounds of formula (II):
- e) when necessary, treating the compounds of formula (I), obtained according to step c) alternatively with: (a) a carboxylic acid in-the presence of a condensing agent; or else (b) carboxylic acid chloride in the presence of a base, or both alternatives in a suitable solvent; to produce the compounds of formula (Ia.).
- 10. A method of using the compounds of formula (I), (Ia) and (II): ##STR41## wherein R represents aryl or heteroaryl, substituted or not substituted, R' represents alkanoyl, alkenoyl, alkynoyl, arenocarbonyl or heteroarenocarbonyl, substituted or not substituted and X represents chlorine, bromine, ioodine or alkyl- or arylsulfonyl, as agents having antitumoral activity for the treatment of cancer.
- 11. The method of use, according to claim 10, of the compound of formula (III): ##STR42## as an agent having antitumoral activity for the treatment of cancer.
- 12. The method of use, according to claim 10, of the compound of formula (IV): ##STR43## as an agent having antitumoral activity for the treatment of cancer.
- 13. The method of use, according to claim 10, of the compound of formula (V): ##STR44## as an agent having antitumoral activity for the treatment of cancer.
- 14. The method of use, according to claim 10, of the compound of formula (IV): ##STR45## as an agent having antitumoral activity for the treatment of cancer.
- 15. The method of use, according to claim 10, of the compound of formula (IIIa): ##STR46## as an agent having antitumoral activity for the treatment of cancer.
- 16. The method of use, according to claim 10, of the compound of formula (IIIb): ##STR47## as an agent having antitumoral activity for the treatment of cancer.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9302430 |
Nov 1993 |
ESX |
|
Parent Case Info
This application is a Continuation of application Ser. No. 08/491,870, filed May 15, 1996 now pending, which is a 371 of PCT/ES94/00122 filed Nov. 18, 1994.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5070092 |
Kanda et al. |
Dec 1991 |
|
Foreign Referenced Citations (4)
Number |
Date |
Country |
0359454-A |
Mar 1990 |
EPX |
406749 |
Jan 1991 |
EPX |
8-034789 |
Feb 1996 |
JPX |
9116324-A |
Oct 1991 |
WOX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
491870 |
May 1996 |
|